Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: A lethal two-way street

被引:78
作者
Zeytun, A
Hassuneh, M
Nagarkatti, M
Nagarkatti, PS
机构
[1] VIRGINIA TECH,VIRGINIA MARYLAND REG COLL VET MED,DEPT BIOL,BLACKSBURG,VA 24061
[2] VIRGINIA TECH,VIRGINIA MARYLAND REG COLL VET MED,DEPT BIOMED SCI & PATHOBIOL,BLACKSBURG,VA 24061
关键词
D O I
10.1182/blood.V90.5.1952
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the current study, we investigated the repercussions of the interaction between tumor cells (LSA) and the tumor-specific cytotoxic T lymphocyte (CTL) (PE-9) when both expressed Fas and Fas ligand (Fast). The CTL clone, PE9, expressed high levels of Fas and Fast upon activation through the T-cell receptor (TCR). Furthermore, the activated PE-9 cells used both perforin-and Fast-based pathways to kill Fas-positive (Fas(+)) LSA tumor cells. Interestingly, LSA tumor cells also constitutively expressed Fast but not perforin, and killed Fas(+) PE-9 CTLs and Fas(+) but not Fas-negative (Fas(-)) activated T cells and thymocytes, as detected using the JAM test. PE-9 CTLs, cultured for 24 hours in the presence of cell lysates of Fast-bearing LSA cells but not FasL-deficient P815 cells, exhibited significant apoptosis as detected using the TUNEL method. Moreover, another Fast(+) T-cell lymphoma line, EL-4, induced apoptosis in Fas(+) but not in Fas(-) T cells in a similar fashion. The current study demonstrates for the first time that not only can the tumor-specific CTL mediate Fas-based killing of tumor cells, but FasL(+) tumor cells can kill the Fas(+) tumor-specific CTL. Thus, the survival of the tumor or the host may depend on which cell can accomplish this task more efficiently, The current study also suggests that Fast-based killing of CTLs by specific tumor cells may constitute a major limiting factor in successful immunotherapy. (C) 1997 by The American Society of Hematology.
引用
收藏
页码:1952 / 1959
页数:8
相关论文
共 27 条
[11]   Evidence for the induction of apoptosis in thymocytes by 2,3,7,8-tetvachlorodibenzo-p-dioxin in vivo [J].
Kamath, AB ;
Xu, HM ;
Nagarkatti, PS ;
Nagarkatti, M .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 142 (02) :367-377
[12]  
Kataoka T, 1996, J IMMUNOL, V156, P3678
[13]   RESISTANCE OF CYTOTOXIC LYMPHOCYTES-T TO LYSIS BY A CLONE OF CYTOTOXIC LYMPHOCYTES-T [J].
KRANZ, DM ;
EISEN, HN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (10) :3375-3379
[14]   Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice [J].
Lau, HT ;
Yu, M ;
Fontana, A ;
Stoeckert, CJ .
SCIENCE, 1996, 273 (5271) :109-112
[15]   THE JAM TEST - A SIMPLE ASSAY FOR DNA FRAGMENTATION AND CELL-DEATH [J].
MATZINGER, P .
JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 145 (1-2) :185-192
[16]  
NAGARKATTI M, 1985, J IMMUNOL, V135, P1510
[17]  
NAGARKATTI M, 1989, CANCER RES, V49, P6587
[18]   CONSTITUTIVE ACTIVATION OF THE INTERLEUKIN-2 GENE IN THE INDUCTION OF SPONTANEOUS IN-VITRO TRANSFORMATION AND TUMORIGENICITY OF T-CELLS [J].
NAGARKATTI, M ;
HASSUNEH, M ;
SETH, A ;
MANICKASUNDARI, K ;
NAGARKATTI, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) :7638-7642
[19]   Fas ligand and immune evasion [J].
Nagata, S .
NATURE MEDICINE, 1996, 2 (12) :1306-1307
[20]   The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand [J].
OConnell, J ;
OSullivan, GC ;
Collins, JK ;
Shanahan, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (03) :1075-1082